Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.

Shim M, Bang WJ, Oh CY, Lee YS, Cho JS

Investigative and clinical urology21 May 2019Cited by 28 (Europe PMC)

PMID31294133PMCIDPMC6607074DOI10.4111/icu.2019.60.4.244PepBankPUB-31294133

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In prostate cancer patients, chemical castration below 50 ng/dL did not differ significantly among triptorelin, goserelin and leuprolide.
In plain wordsIn prostate cancer patients, triptorelin and the other drugs had similar castration rates below 50 ng/dL.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeChemical castration below 50 ng/dL
Study
n = 125
Comparator
Goserelin and leuprolide
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg · 9 monthsAs given in this study (human).
Source sentences
Summary
Significant differences in chemical castration levels were observed only at <10 ng/dL, with 54.2% of goserelin, 93.2% of triptorelin, and 86.4% of leuprolide treated patients (p<0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
The number of patients with serum testosterone below castration levels defined as various values (<50 ng/dL, <20 ng/dL, or <10 ng/dL) at 3, 6, and 9 months were also evaluated.
Summary · context
We retrospectively reviewed the medical records of 125 patients with prostate cancer treated with luteinizing hormone-releasing hormone (LHRH) agonists between January 2009 and December 2015.
Summary · context
Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg were analyzed using a mixed model.
Summary · context
Of the 125 patients, 59 received goserelin, 44 received triptorelin, and 22 received leuprolide, respectively.
Report a problemFND-3129413305
02HumanObservational studyEfficacy outcome
In prostate cancer patients, chemical castration below 20 ng/dL did not differ significantly among triptorelin, goserelin and leuprolide.
In plain wordsIn prostate cancer patients, triptorelin and the other drugs had similar castration rates below 20 ng/dL.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeChemical castration below 20 ng/dL
Study
n = 125
Comparator
Goserelin and leuprolide
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg · 9 monthsAs given in this study (human).
Source sentences
Summary
Significant differences in chemical castration levels were observed only at <10 ng/dL, with 54.2% of goserelin, 93.2% of triptorelin, and 86.4% of leuprolide treated patients (p<0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
The number of patients with serum testosterone below castration levels defined as various values (<50 ng/dL, <20 ng/dL, or <10 ng/dL) at 3, 6, and 9 months were also evaluated.
Summary · context
We retrospectively reviewed the medical records of 125 patients with prostate cancer treated with luteinizing hormone-releasing hormone (LHRH) agonists between January 2009 and December 2015.
Summary · context
Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg were analyzed using a mixed model.
Summary · context
Of the 125 patients, 59 received goserelin, 44 received triptorelin, and 22 received leuprolide, respectively.
Report a problemFND-3129413306
03HumanObservational studyEfficacy outcome
In prostate cancer patients, triptorelin was linked to lower mean testosterone than goserelin during treatment.
In plain wordsIn prostate cancer patients, triptorelin was linked to lower mean testosterone than goserelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseMean testosterone versus goserelin
Study
n = 103
Comparator
Goserelin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg · 9 monthsAs given in this study (human).
Source sentences
Summary
The lowest mean testosterone levels during 9 months of treatment were achieved in patients treated with triptorelin, followed by those treated with leuprolide, and then by those treated with goserelin (p=0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively reviewed the medical records of 125 patients with prostate cancer treated with luteinizing hormone-releasing hormone (LHRH) agonists between January 2009 and December 2015.
Summary · context
Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg were analyzed using a mixed model.
Summary · context
Of the 125 patients, 59 received goserelin, 44 received triptorelin, and 22 received leuprolide, respectively.
Report a problemFND-3129413301
04HumanObservational studyEfficacy outcome
In prostate cancer patients, testosterone below 10 ng/dL occurred in 93.2% with triptorelin versus 54.2% with goserelin.
In plain wordsIn prostate cancer patients, triptorelin was linked to more testosterone suppression below 10 ng/dL than goserelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseChemical castration below 10 ng/dL versus goserelin
Study
n = 103
Comparator
Goserelin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg · 9 monthsAs given in this study (human).
Measurements
Patients with testosterone below 10 ng/dL
93.2%
triptorelin
Patients with testosterone below 10 ng/dL
54.2%
goserelin
Source sentences
Summary
Significant differences in chemical castration levels were observed only at <10 ng/dL, with 54.2% of goserelin, 93.2% of triptorelin, and 86.4% of leuprolide treated patients (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively reviewed the medical records of 125 patients with prostate cancer treated with luteinizing hormone-releasing hormone (LHRH) agonists between January 2009 and December 2015.
Summary · context
Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg were analyzed using a mixed model.
Summary · context
Of the 125 patients, 59 received goserelin, 44 received triptorelin, and 22 received leuprolide, respectively.
Report a problemFND-3129413303
05HumanObservational studyEfficacy outcome
In prostate cancer patients, triptorelin was linked to lower mean testosterone than leuprolide during treatment.
In plain wordsIn prostate cancer patients, triptorelin was linked to lower mean testosterone than leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseMean testosterone versus leuprolide
Study
n = 66
Comparator
Leuprolide
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg · 9 monthsAs given in this study (human).
Source sentences
Summary
The lowest mean testosterone levels during 9 months of treatment were achieved in patients treated with triptorelin, followed by those treated with leuprolide, and then by those treated with goserelin (p=0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively reviewed the medical records of 125 patients with prostate cancer treated with luteinizing hormone-releasing hormone (LHRH) agonists between January 2009 and December 2015.
Summary · context
Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg were analyzed using a mixed model.
Summary · context
Of the 125 patients, 59 received goserelin, 44 received triptorelin, and 22 received leuprolide, respectively.
Report a problemFND-3129413302
06HumanObservational studyEfficacy outcome
In prostate cancer patients, testosterone below 10 ng/dL occurred in 93.2% with triptorelin versus 86.4% with leuprolide.
In plain wordsIn prostate cancer patients, triptorelin was linked to more testosterone suppression below 10 ng/dL than leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseChemical castration below 10 ng/dL versus leuprolide
Study
n = 66
Comparator
Leuprolide
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg · 9 monthsAs given in this study (human).
Measurements
Patients with testosterone below 10 ng/dL
93.2%
triptorelin
Patients with testosterone below 10 ng/dL
86.4%
leuprolide
Source sentences
Summary
Significant differences in chemical castration levels were observed only at <10 ng/dL, with 54.2% of goserelin, 93.2% of triptorelin, and 86.4% of leuprolide treated patients (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively reviewed the medical records of 125 patients with prostate cancer treated with luteinizing hormone-releasing hormone (LHRH) agonists between January 2009 and December 2015.
Summary · context
Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg were analyzed using a mixed model.
Summary · context
Of the 125 patients, 59 received goserelin, 44 received triptorelin, and 22 received leuprolide, respectively.
Report a problemFND-3129413304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 4Current
27 Oct 2026, 16:37 UTC
The same notice was added 2 times, first on 27 Oct 2026, 16:35 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.

Summary

Results from this study6

Version history

Subjects

Publication types

MeSH terms

Keywords